Recent advances in the treatment of opioid use disorders–focus on long-acting buprenorphine formulations-Reference-Cited by-同舟云学术

Recent advances in the treatment of opioid use disorders–focus on long-acting buprenorphine formulations

Published:2021-09-19 Issue:9 Volume:11 Page:543-552
ISSN:2220-3206
Container-title:World Journal of Psychiatry
language:
Short-container-title:WJP

Author:

Soyka Michael,Franke Andreas G

Publisher

Baishideng Publishing Group Inc.

Reference73 articles.

1. The global epidemiology and burden of opioid dependence: results from the global burden of disease 2010 study

2. Global patterns of opioid use and dependence: harms to populations, interventions, and future action

3. Neusser S, Treutner A, Pomorin N Wasem A, Neumann A. Krankheitskosten der Opioidabhängigkeit in Deutschland. Suchtmed 2020; 22: 205-216

4. Treatment of Opioid-Use Disorders

5. EMCDDA. European Monitoring Centre for drugs and Drug addiction (2020) European Drug Report. Lisbon: EMCDDA. [cited 10 January 2021]. Available from: https://www.drugsandalcohol.ie/33049/

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Surgical removal of extended-release buprenorphine depot due to adverse reactions;The American Journal of Emergency Medicine;2024-07

2. Feasibility and effectiveness of extended-release buprenorphine (XR-BUP) among correctional populations: a systematic review;The American Journal of Drug and Alcohol Abuse;2024-06-28

3. Long-acting injectable buprenorphine in the real world: case report on dual disorders;Journal of Addictive Diseases;2024-05-21

4. Buprenorphine extended-release injection (Brixadi®) in the management of opioid use disorder: a profile of its use in the USA;Drugs & Therapy Perspectives;2024-02

5. Opioid agonist treatment in transition: A cross-country comparison between Austria, Germany and Switzerland;Drug and Alcohol Dependence;2024-01